Collectively, these data indicate that 249C is efficacious in inhibiting tumor growth with minimal side effects (Supplementary Fig. 12) in our investigations thus far, establishing in vivo proof-of-concept for targeting autophagy/MP/lysosomal acidification with 249C in mutant KRAS cancers. The gene discussed is KRAS; the disease is cancer.